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ABSTRACT
10 Rta is a transcription factor encoded by BRLF1 of
theEpstein–Barrvirus(EBV).Thisfactorisexpressed
during the immediate-early stage of the lytic cycle
to activate the genes required for EBV lytic develop-
ment. Although transcription activation by Rta is
15 frequently associated with the binding of Rta to the
Rta-response element (RRE) in promoters, Rta some-
times activates promoters without an RRE. Here we
show that Rta interacts with an Sp1-interacting pro-
tein, MBD1-containing chromatin-associated factor 1
20 (MCAF1). This interaction is critical to the forma-
tion of an Sp1–MCAF1–Rta complex at Sp1 sites.
Therefore, following lytic induction and the expres-
sionofRta,RtaincreasesSp1-mediatedtranscription.
The genes that are thus activated include p16, p21,
25 SNRPN and BRLF1. However, the binding of Rta
to RRE prevents the interaction between Rta and
MCAF1; therefore, transcription activation by RRE
depends only on Rta, and not on MCAF1 or Sp1.
Furthermore, this study finds that MCAF1 promotes
30 the expression of Rta and Zta from EBV, indicating
that MCAF1 participates EBV lytic activation. Our
study documents the critical role of Rta in regulat-
ing the transcription of the genes that are mediated
by Sp1.
35 INTRODUCTION
Rta, encoded by BRLF1, is a transcription factor expressed by
Epstein–Barr virus (EBV) during the immediate-early stage
of the lytic cycle. This factor often cooperates with another
EBV immediate-early protein, Zta, to activate synergistic-
40 ally the transcription of EBV lytic genes (1–3). These two
immediate-early proteins are crucial to EBV lytic activation
because mutants that do not produce either one of these
two proteins do not produce infectious EBV particles (4).
Earlier studies have established that Rta frequently activates
45 transcription by binding to a 17 bp cis sequence, the Rta-
response element (RRE) (5). The EBV genes that are activated
in this way include BMRF1, BHRF1, BHLF1 and BMLF1
(2,3,6–9). However, Rta also activates the transcription of
BRLF1, BZLF1, BALF5 and BNLF1 of EBV, which lack
50 an RRE in their promoter (10–13). Although exactly how Rta
activates these promoters is unclear, an earlier work demon-
strated that the Sp1 sites in the BRLF1 promoter (Rp) are
critical to the activation by Rta (10). However, Rta does
not appear to interact directly with Sp1 to activate the
55 transcription (10).
MBD1-containing chromatin-associated factor 1 (MCAF1),
a human homolog of murine ATFa-associated modulator, is a
transcription factor of 1270 amino acids with a transcriptional
repression activity (14). MCAF1 enhances SETDB1/ESET-
60 mediated histone H3 methylation (15) to promote the forma-
tion of heterochromatin domains (16). MCAF1 also interacts
with MBD1 and Sp1 (14). The interaction between MCAF1
and MBD1 is crucial to MBD1-dependent transcriptional
repression (14); when it binds to MBD1, MCAF1 forms a
65 repressive complex with MBD1 to prevent transcription from
a methylated promoter (14). However, when binding to Sp1,
MCAF1 becomes a coactivator to enhance Sp1-mediated tran-
scription (14). This work ﬁnds that Rta interacts with MCAF1,
which facilitates the formation of an Sp1–MCAF1–Rta
70 complex on the Sp1-binding site to autoregulate the transcrip-
tion of BRLF1 and regulate the host genes in EBV-infected
cells.
MATERIALS AND METHODS
Cell lines and EBV lytic induction
75 P3HR1 cells were cultured in RPMI 1640 medium that con-
tained 10% fetal calf serum (FCS). 293T and 293 cells were
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doi:10.1093/nar/gki956cultured in DMEM supplemented with 10% FCS. P3HR1 cells
were treated with 3 ng/ml of 12-O-tetradecanoylphobol-
13-acetate (TPA) and 3 mM sodium butyrate to activate the
EBV lytic cycle (17). Maxi-EBV is a laboratory-constructed
5 EBV strain that contains an F replicon (18).
Plasmids
Plasmid pCMV-R contains BRLF1 transcribed from the
cytomegalovirus (CMV) immediate-early promoter. Plasmids
pcDNA-MCAF1, pHA-Rta, pRRE, pRp-luc, pCMV-
10 R(K213A) and pET-Rta were described elsewhere (17,19).
Plasmid pGEX-4T1, which expresses GST, was purchased
from Amersham Pharmacia Biotech (Hong Kong). The
DNA fragment that encodes p621 (amino acids 650–1270
of MCAF1) was isolated from pcDNA-MCAF1 (14) by
15 HpaI–XhoI digestion and inserted into the SmaI and XhoI
sites to yield plasmid pGST-621. The Sp1 gene was ampliﬁed
by PCR, using GST-Sp1 (50-CCGGAATTCATGGATG-
AAATGACAGCTGTG) and Sp1-His (50-ACGCGTCGAC-
AAGCCATTGCCACTGATA) as primers, and plasmid
20 pCMV-Sp1 (20), which was obtained from Guntram Suske,
as a template. The fragment was inserted into the EcoRV and
SalI sites of pET32a or pGEX-4T1 to form plasmid pET-Sp1
or pGST-Sp1, respectively. Plasmid pR-Sp1 was construc-
ted by inserting a double-stranded oligonucleotide that con-
25 tained a sequence that covers the region between  53 and +4
of Rta, into the SmaI site of pGL2-Basic (Promega Corp.,
Madison, WI). In this sequence (50-GTCCCGCCCATGCC-
AGATATCCATAAAAGACCAGTAATCCATGTCAGCCG-
GCCTTT), a ZRE sequence and a nucleotide residue that
30 precedes the sequence was mutated from 50-ATGGCTCA to
50-GATATCCA (Fig. 1). The Sp1 site (50-CCGCCC), the
mutated ZRE sequence and the TATA sequence (5-AT-
AAAA) are underlined. Plasmid pR-mSp1 includes the same
sequence as pR-Sp1, except in that the Sp1 site, 50-CCGCCC,
35 was changed to 50-ATTAAT. R-TATA (50-CATAAAAGAC-
CAGTAATCCATGTCAGCCGGCCTTT), which contains a
sequence from the region from  32 to +4 in Rp, was inserted
into the SmaI site of pGL2-Basic to construct plasmid pTA.
Plasmid pSp1-luc contains four of the six Sp1-binding sites
40 from the promoter of p21 upstream of the ﬁreﬂy luciferase
gene (luc) in pTA. Plasmid pFlag-Rta that expresses full-
length Flag-tagged Rta was constructed by inserting a PCR-
ampliﬁed BRLF1 fragment into pCMV-Tag2A (Stratagene) at
the EcoRIandXhoIsites. Thesameapproachwasemployedto
45 produce deletions in Flag-tagged Rta (Flag-Stu, Flag-HincII,
Flag-HinfI and Flag-EcoRII), which lacked the regions
between amino acids 1 and 190, 1 and 254, 1 and 290, and
1 and 360, respectively. Plasmid pEGFP-MCAF1-N, which
contains the N-terminal 561 amino acids of MCAF1, was
50 constructed by inserting a PCR-ampliﬁed fragment into the
HindIII and SmaI sites of pEGFP-C1 (Clontech). Plasmids
pEGFP-MCAF1-D1 and pEGFP-MCAF1-D2 were also con-
structed using the same strategy. An Rta deletion mutant,
HA-RN290 that contains the N-terminal 290 amino acids of
55 Rta was constructed by inserting a PCR fragment into the
EcoRI and XhoI sites of pcDNA3-HA. Plasmid pEGFP-
R255/290, which encodes the region between amino acid
255 and 290 in Rta fused with green ﬂuorescence protein
(GFP),wasconstructedbyinsertingaPCR-ampliﬁedfragment
60 into the EcoRI and SalI sites of pEGFP-C1. Plasmid pp21-luc
was obtained from W.-C. Hung. Plasmids pp16-luc and
pSNRPN-luc have been described elsewhere (14).
Yeast two-hybrid screen
The binding partners of Rta were identiﬁed by yeast two-
65 hybrid screen with a bait plasmid, pR476, and a human testes
cDNA library, following a method described elsewhere (17).
GST-pull-down assay
GST or GST-p621 at a concentration of 40 ng/ml in 500 mlo f
NETN buffer (20 mM Tris–HCl, pH 8.0, 100 mM NaCl, 1 mM
70 EDTA and 0.5% NP-40), containing 10 mg/ml each of
leupeptin, aprotinin and 4-(2-aminoethyl)-benzenesulfonyl
ﬂuoride, was added to 30 ml of glutathione–Sepharose 4B
beads (Amersham Pharmacia Biotech). The mixture was
incubated with shaking for 1 h at 4 C. The beads were washed
75 three times in NETN buffer and added to a lysate (300 ml)
prepared from Escherichia coli BL21(DE3)(pET-Rta) or
E.coli BL21(DE3)(pET-Sp1). The reaction mixture was
incubated on ice for 1 h. The beads were then washed in
NETN buffer. An equal volume of 2· electrophoresis sample
80 buffer was added to the mixture and proteins were extracted
from the beads by heating at 95 C for 5 min. Proteins were
ﬁnally separated by SDS–PAGE (21).
Immunoprecipitation
P3HR1 cells (1 · 10
7) treated with TPA and sodium butyrate
85 were washed in phosphate-buffered saline (PBS). Lysate
was prepared using radioimmune precipitation assay (RIPA)
buffer, following a method described elsewhere (17). To the
supernatant, anti-Rta (1:500 dilution) (Argene, Varilhes,
France), anti-MCAF1 antibody (1:500 dilution) (14) or anti-
90 Sp1 antibody (1:2000 dilution) (Santa Cruz Biotechnology
Inc., Santa Cruze, CA) was added and incubated at 4 C for
1 h. Protein-A/G agarose beads (30 ml) (Oncogene, Boston,
MA) were added to the lysate and the mixture was incubated
with shaking for 1 h at 4 C. The beads were ﬁnally collected
95 by centrifugation and washed three times in RIPA buffer.
Proteins that bound to the beads were eluted by adding
20 mlo f2 · electrophoresis sample buffer and analyzed by
immunoblotting (IB) with anti-Rta, anti-MCAF1 or anti-Sp1
antibody.
100 DNA-affinity precipitation assay (DAPA)
A5 0-biotin end-labeled double-stranded probe (Rp64/28)
that contains a sequence from  64 to  28 in Rp (50-ATAT-
TGCGATTGTCCCGCCCATGCCAATGGCTCATAA), was
synthesized by Mission Biotech, Inc. (Taipei, Taiwan). A mut-
105 ant probe (mRp28/64), with the same sequence except in that
the Sp1 site was changed from 50-CCGCCC to 50-ATTAAT,
was used as a negative control. In both Rp64/28 and Rpm64/
28, the ZRE in Rp was mutated from 50-TGAGCCA to
50-TGCAGTC (Fig. 1). A biotin-labeled probe that contained
110 an RRE sequence (50-CATGTCCCTCTATCATGGCG-
CAGAC) from the BMLF1 promoter was utilized to demon-
strate the binding of Rta to RRE. A cell lysate prepared from
P3HR1 cells treated with TPA/sodium butyrate or 293T cells
transfected with pCMV-R was mixed with 0.2 mg of a biotin-
115 labeled probe in a binding buffer that contained 60 mM KCl,
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0.5 mM EDTA, 1 mM DTT and 10 mg/ml each of leupeptin,
aprotinin and 4-(2-aminoethyl)-benzenesulfonyl ﬂuoride.
After it was incubated on ice for 45 min, DNA–protein com-
5 plexes were then incubated with 30 ml of Streptavidin
MagneSphere Paramagnetic particles (Promega Corp.),
which were pre-equilibrated in the binding buffer with gentle
shaking for 1 h at 4 C. DNA–protein complexes were
then washed ﬁve times in the binding buffer. Next, 2·
10 electrophoresis sample buffer was added to the precipitated
DNA–protein complexandthesolutionwasboiledfor5minto
dissociate the complexes. Finally, the proteins were resolved
by PAGE and detected by IB.
Chromatin immunoprecipitation (CHIP) assay
15 CHIP assay was performed according to a method described
previously (19). P3HR1 cells (1 · 107) were transfected
with pcDNA-MCAF1, pCMV-R and pR-Sp1 or pR-mSp1.
Formaldehyde-ﬁxed DNA–proteins complex was immuno-
precipitated with anti-Rta, anti-Sp1 or anti-MCAF1 antibody.
20 The presence of Rp fragments in the precipitates was detected
by PCR, using R-TATA1 (50-AAAGGCCGGCTGACATGG-
ATTACTGGTCTTTTATG) and F1 (50-GGTACGTGGAG-
GTTTTAC) as primers. PCR was performed for 28 cycles
under the conditions of 30 s at 94, 51 and 72 C.
25 Immunofluorescence analysis
P3HR1 cells were transfected with pCMV-R. After culturing
for 24 h, cells were harvested by centrifugation; plated on
poly-L-Lysine (Sigma)-coated coverslips, and ﬁxed with 4%
paraformaldehyde in PBS for 30 min. Immunostaining was
30 conducted with anti-Rta monoclonal antibody, rabbit anti-
MCAF1 polyclonal antibody and rabbit anti-Sp1 polyclonal
antibody. The cells were then treated with ﬂuorescein
isothiocyanate-conjugated donkey anti-mouse IgG polyclonal
antibody (KPL Inc., Gaithersburg, MD) or rhodamine-
35 conjugated donkey anti-rabbit IgG polyclonal antibody
(DAKO, Glostrup, Denmark), following a method described
elsewhere (17). Nuclei were visualized by staining with
5 mg/ml of 40-6-diamidino-2-phenylindole (DAPI). Finally,
cells were examined using an Olympus confocal laser-
40 scanning microscope (Model Fluoview 500).
Transient transfection assay
Plasmids (10 mg) were transfected into P3HR1 or 293T cells
by electroporation with a BioRad Gene-Pulser electroporator
(Richmond, CA) (22). Luciferase assay was performed,
45 using a luminometer (model LB593; Berthod, Bad Wildbad,
Germany), according to a method described elsewhere (22).
Each transfection experiment was performed three times and
each sample in each experiment was prepared in duplicate.
RESULTS
50 InteractionamongSp1,p621andRtainyeastandinvitro
A yeast two-hybrid screen was performed with pR476, which
encodes the N-terminal 476 amino acids of Rta, to screen
a human testes cDNA library constructed in pACT2. Of the
24 clones that produce a protein interacting with Rta, one
55 cDNA clone encoded p621 (23), which interacts with Sp1
and has a sequence identical to that in the C-terminal 621
amino acid region of a 1270 amino acid protein, MCAF1
(14). The interaction between Rta and p621 was further veri-
ﬁed by transforming the plasmid that expresses p621 into the
60 yeast strain Y190(pR476). A GST-pull-down assay was then
performed with a bacterially expressed GST–p621 fusion
protein. GST or GST–p621 bound to glutathione–Sepharose
beads were added to the lysate that had been prepared
from P3HR1 cells treated with TPA and sodium butyrate.
65 After extensive washing, proteins bound to the beads were
eluted and analyzed by IB with anti-Rta antibody. The results
revealed that Rta in the lysate (Figure 2A, lane 1) was retained
by GST–p621–glutathione–Sepharose (Figure 2A, lane 3) but
not by GST–glutathione–Sepharose beads (Figure 2A, lane 2).
70 IB with anti-Sp1antibody alsoproduceda similar result, indic-
ating that Sp1 in the lysate (Figure 2B, lane 1) was retained by
GST–p621–glutathione–Sepharose (Figure 2B, lane 3) but not
by GST–glutathione–Sepharose beads (Figure 2B, lane 2). In
parallel experiments, MCAF1 in the P3HR1 lysate (Figure 2C,
75 lane 1) was retained by GST–Rta- and GST–Sp1- (Figure 2C,
lanes 3 and 4) but not by GST–glutathione–Sepharose beads
(Figure 2C, lane 2). Bacterially expressed His-tagged Sp1,
GST–p621 and His-tagged Rta were mixed to elucidate
whether Sp1 and Rta simultaneously bind to p621. In a reac-
80 tionmixturethatcontainedallthreeproteins,Rtawasimmuno-
precipitated by anti-Sp1 antibody (Figure 2D, lane 5).
However, Rta was not immunoprecipitated by anti-Sp1 anti-
body when GST–p621 was not added to the binding mixture
(Figure 2D, lane 4). In negative controls, anti-HA antibody,
85 which was used as a nonspeciﬁc antibody, did not immuno-
precipitate Rta even when GST–621 was present in the reac-
tion mixture (Figure 2D, lanes 2 and 3). Rta did not inhibit
the association of Sp1 with MCAF1, even the addition of
60 mg of Rta in the binding reaction did not inﬂuence the
90 binding of Sp1 to MCAF1 (Figure 2E).
Coimmunoprecipitation of Sp1, MCAF1 and Rta
293T cells were cotransfected with pCMV-R and pcDNA-
MCAF1. A lysate was subsequently prepared and proteins
Figure 1. Reporter plasmids and the DNA fragments used in this study.
Numbersrepresentthe nucleotidepositionsin relationto the +1 siteof BRLF1.
A Zif268 site, located at  45, is not shown. A ZRE located close to the TATA
box of Rp was mutated. Rp, the BRLF1 promoter; Sp1, Sp1-binding sequence;
ZRE, Zta-response element; TATA, TATA box; 4XSp1: four Sp1 sites in
the p21 promoter.
6530 Nucleic Acids Research, 2005, Vol. 33, No. 20in the lysate were immunoprecipitated with anti-Rta and
anti-MCAF1 antibody. IB revealed that Rta was immuno-
precipitated by anti-Rta antibody (Figure 3A, lane 3) and
coimmunoprecipitated with MCAF1 by anti-MCAF1 antibody
5 (Figure 3A, lane 4); MCAF1 was also immunoprecipitated by
anti-MCAF1 antibody (Figure 3A, lane 8) and coimmuno-
precipitatedbyanti-Rtaantibody(Figure3A,lane7).Immuno-
blot analysis also showed that Rta was immunoprecipitated by
anti-Rta antibody (Figure 3B, lane 3) and coimmuno-
10 precipitated by anti-Sp1 antibody (Figure 3B, lane 4). In
parallel, Sp1 was immunoprecipitated by anti-Sp1 antibody
(Figure 3B, lane 8) and coimmunoprecipitated by anti-Rta
antibody (Figure 3B, lane 7). A similar study was performed
with the lysate from P3HR1 cells that were treated with TPA
15 and sodium butyrate (Figure 3, panels C and D). Immunoblot
analysis revealed that Rta was coimmunoprecipitated by
Figure 3. Coimmunoprecipitation of Sp1, MCAF1 and Rta. Anti-Rta and anti-MCAF1 antibody were added to the lysates prepared from 293T cells transfected
with pCMV-R and pcDNA-MCAF1 (A and B) or from P3HR1 cells that were treated with TPA and sodium butyrate (C and D). Proteins in the lysate immuno-
precipitated by the anti-Rta antibody, anti-MCAF1 antibody or anti-Sp1 antibody were analyzed by IB with anti-Rta antibody (A–D, lanes 1–4), anti-MCAF1
antibody (A and C, lanes 5–8) and anti-Sp1 antibody (B and D, lanes 5–8). Reactions involving anti-IgG antibody were used as negative controls.
Figure 2. Interaction among Sp1, p621 and Rta in vitro. GST–p621 was added to the lysate prepared from P3HR1 cells treated with TPA and sodium butyrate.
ProteinsboundtoGST–p621werepulleddownwithglutathione–Sepharosebeads(Beads)andanalyzedbyIBusinganti-Rta(A)andanti-Sp1antibody(B).Parallel
experiments involving GST–Rta (lane 3) and GST–Sp1 (lane 4) were also conducted and IB was performed with anti-MCAF1 antibody (C). Meanwhile, anti-HA
antibody (lanes 2 and 3) and anti-Sp1 antibody (lanes 4 and 5) were added to mixtures containing Sp1, GST–p621 and Rta to determine whether the interaction
betweenSp1andRtarequiresp621(D).VariousamountsofRtawereaddedtobindingmixturesthatcontainedSp1andGST–p621.Proteinswerepulleddownusing
GST–p621–glutathione–Sepharose beads and analyzed by IB with anti-Sp1 antibody (E). In each part, lane 1 was loaded with cell lysate; in lane 2, proteins were
eluted from GST–glutathione–Sepharose beads.
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(Figure 3C, lane 7). Additionally, Rta was coimmunoprecip-
itated by anti-Sp1 antibody (Figure 3D, lane 3) and vice versa
(Figure 3D, lane 7).
5 Subcellular localization of Rta, MCAF1 and Sp1
Immunoﬂuorescence analysis of P3HR1 cells was performed
with confocal microscopy to locate Sp1, MCAF1 and Rta in
the cell. After transfection with pCMV-R, Rta was detected
in the nucleus and in the cytoplasm (Figure 4B and J). How-
10 ever, MCAF1 and Sp1 were detected only in the nucleus
(Figure 4C, G, K and O). Merged pictures revealed that
MCAF1 (Figure 4D) and Sp1 (Figure 4L) were colocalized
with Rta in the nucleus. Colocalization was not observed,
however, in the cells that had been transfected with an
15 empty vector (Figure 4H and P).
Binding of the Sp1–MCAF1–Rta complex to the Sp1 site
A double-stranded 37 bp biotin-labeled Sp1 probe, Rp64/28
(Figure 1), which contains the sequence in the region between
 64 and  28 of Rp, was added to a lysate prepared from
20 P3HR1 cells treated with TPA and sodium butyrate. Immun-
oblot analysis revealed that Sp1, MCAF1 and Rta were
bound to the probe (Figure 5), but these proteins did not
bind to a mutant probe, Rpm64/28 (Figure 5), whose sequence
is identical to that of Rp64/28, except for a mutated
25 Sp1-binding sequence (Figure 1).
Binding of the Sp1–MCAF1–Rta complex to the
Sp1 sites in vivo
CHIP analysis was performed to demonstrate the binding of
Sp1, MCAF1 and Rta, to the Sp1 site on pR-Sp1 (Figure 6).
30 Meanwhile, a parallel experiment was conducted with
Figure 4. Indirect immunofluorescence analysis. P3HR1 cells were transfected with pCMV-R (A–D, I–L) or an empty vector (E–H, M–P). Cells were incubated
with monoclonal anti-Rta antibody (B, F, J and N), rabbit anti-MCAF1 polyclonal antibody (C and G) and rabbit anti-Sp1 polyclonal antibody (K and O).
DAPI staining revealed the positions of the nucleus. Finally, cells were examined using a confocal laser-scanning microscope. D, H, L and P are merged images.
Figure 5. Binding of the Sp1, MCAF1 and Rta to an Sp1-binding site on Rp.
A biotin-labeled double-stranded Sp1 probe (Rp64/28) that contains the
sequence from  64 and  28 of Rp was added to a lysate prepared from
P3HR1 cells treated with TPA and sodium butyrate. A probe with an identical
sequence, except for a mutated Sp1-binding sequence (Rpm64/28), was used
as a negative control. Proteins bound to the probes were captured with strepta-
vidinmagneticbeads,extractedanddetectedbyIBwithanti-Sp1,anti-MCAF1
and anti-Rta antibodies.
6532 Nucleic Acids Research, 2005, Vol. 33, No. 20pR-mSp1 whose sequence is identical to that of pR-Sp1,
except in that the Sp1 sequence in Rp was mutated
(Figure 1). P3HR1 cells were cotransfected with pcDNA-
MCAF1, pCMV-R and pR-Sp1. After the cells were treated
5 with formaldehyde to cross-link DNA and proteins, DNA was
isolated, sonicated and immunoprecipitated with anti-Sp1,
anti-MCAF1 and anti-Rta antibody. PCR ampliﬁcation of
immunoprecipitated DNA with primers that are comple-
mentary to the vector sequences that ﬂank the Rp segment
10 in pR-Sp1 demonstrated that these three antibodies immuno-
precipitated the Rp segment (Figure 6, lanes 3–5). The DNA
fragment was not ampliﬁed by PCR if anti-IgG antibody
was utilized to immunoprecipitate DNA (Figure 6, lane 2).
The Rp sequence was undetected when pR-mSp1 was cotrans-
15 fected into the cells (Figure 6, lanes 7–10). In this work,
the ZRE sequence in Rp in both pR-Sp1 and pR-mSp1 was
purposely mutated (Figure 1). Mutating this ZRE sequence
was necessary to detect the binding of Sp1, MCAF1 and
Rta to the Sp1 site by CHIP analysis, because according to
20 our unpublished results, MCAF1 and Rta interact with Zta
and form a complex on ZRE.
Mapping the interaction domains in MCAF1 and Rta
Plasmids that expressed Rta and derivatives of MCAF1 fused
to GFP (Figure 7A) were cotransfected into 293T cells.
25 Immunoblot analysis revealed that a GFP fusion protein,
which contained the region between amino acids 562 and
981 of MCAF1 (GFP-MCAF1-D1), was coimmunoprecipit-
ated with Rta by anti-Rta antibody (Figure 7B, lane 7). How-
ever, GFP alone (Figure 7B, lane 5) and a GFP fusion protein
30 that contained the region from amino acid 1 to 561 (Figure 7B,
lane 6) or from 982 to 1270 (Figure 7B, lane 8) in MCAF1
were not coimmunoprecipitated by anti-Rta antibody. Thus,
the region between amino acid 562 and 981 in MCAF1 inter-
acts with Rta. Additionally, GST–p621, which contains the
35 region between amino acid 650 and 1270 in MCAF1, binds
to Rta (Figure 2), indicating that the region between amino
acid 650 and 981 in MCAF1 interacts with Rta. We performed
a similar study using Flag-tagged Rta, HA-tagged Rta and
GFP–Rta fusion proteins (Figure 7C) to identify the regions
40 in Rta that interact with MCAF1. Coimmunoprecipitation
with anti-MCAF1 antibody revealed that full-length Rta
(Figure 7D, lanes 2, 8 and 11), the N-terminal 290 amino
acid region (HA-RN290) (Figure 7D, lane 9), Rta without
the N-terminal 190 amino acids (Figure 7D, lane 3) and
45 Rta without the N-terminal 254 amino acids (Figure 7D,
lane 4), interact with MCAF1. Further deleting Rta into the
C-terminal region prevented the proteins from being coim-
munoprecipitated by anti-MCAF1 antibody (Figure 7D,
lanes 5 and 6), indicating that the region between amino
50 acids 255 and 290 in Rta interacts with MCAF1. Furthermore,
immunoblot analysis revealed that a faint band, which
migrated to a position slightly higher than that of the 62 kDa
marker, was nonspeciﬁcally detected by anti-Rta antibody
(Figure 7D, lanes 5 and 6). To conﬁrm that the 255–290
55 amino acid region indeed interacted with MCAF1, a plasmid,
which expresses a protein that contains a GFP sequence in the
N-terminal region fused with the amino acid 255–290 region
of Rta (Figure 7C, lane 12), was transfected into cells. IB with
anti-GFP antibody revealed that anti-MCAF1 antibody coim-
60 munoprecipitated the fusion protein with MCAF1 (Figure 7D,
lane 12) but not GFP (Figure 7D, lane 10).
Involvement of MCAF1 in Rta autoregulation
A reporter plasmid, pRp containing a full-length Rp, from
 963 to +5 in BRLF1, was transfected into P3HR1 cells.
65 The reporter plasmid exhibited a background level of luci-
ferase activity (Figure 8A). Meanwhile, cotransfecting 1 mg
of pcDNA-MCAF1 had little effect on the transcription of
luc from the reporter plasmid (Figure 8A). However, as expec-
ted, transfecting pCMV-R activated the transcription of
70 luc from the reporter plasmid (Figure 8A). Furthermore, trans-
fecting pcDNA-MCAF1 enhanced the transcription of the
luciferase gene activated by Rta in a dose-dependent manner
(Figure 8A). The activity increased to  130, 180 and 300% of
the original value when 1, 3 and 5 mg of pcDNA-MCAF1 were
75 cotransfected, respectively (Figure 8A). Similar results were
obtained when another reporter plasmid, pR-Sp1, which
contained the region between  53 and +8 in Rp (Figure 1),
was transfected (Figure 8B). Luciferase activity exhibited by
the reporter plasmid increased to  200% when pCMV-R and
80 5 mg of pcDNA-MCAF1 were cotransfected into the cells
(Figure 8B). However, although transfecting pCMV-R activ-
ated an RRE-reporter plasmid, pRRE (Figure 8C), cotransfect-
ing pcDNA-MCAF1 did not further increase the transcription
activity in a dose-dependent manner (Figure 8C), indicating
85 that MCAF1 cannot increase the activity of Rta on RRE.
Rta also activated an RRE promoter (pRRE) to a level of
 1.5 times that of an Sp1 promoter (pR-Sp1) (Figure 8D),
indicating that Rta activates an Sp1 promoter almost as
efﬁciently as it does an RRE promoter.
90 Activation of Rta expression and the EBV lytic
cycle by MCAF1
To examine how MCAF1 inﬂuences the expression of Rta,
20 mg of pcDNA3.1 or pcDNA-MCAF1 was transfected into
5 · 10
6 of P3HR1 cells. Immunoblot analysis with anti-Rta
95 antibody did not detect the expression of Rta at 48 h after the
transfection (Figure 9A, lanes 2 and 3). Cotransfecting the
Figure 6. CHIP analysis of the binding of Sp1, MCAF1 and Rta to an Sp1 site
on Rp. P3HR1 cells were cotransfected with pCMV-R, pcDNA-MCAF1 and
pR-Sp1 (lanes 1–5). Meanwhile, in separate experiments, pR-mSp1 (lanes
6–10) rather than pR-Sp1, was cotransfected. Binding of Sp1, MCAF1 and
Rta to the Sp1 site on pR-Sp1 was studied by CHIP analysis using anti-IgG
antibody (lanes 2 and 7), anti-Sp1 antibody (lanes 3 and 8), anti-MCAF1 anti-
body (lanes 4 and 9) and anti-Rta antibody (lanes 5 and 10). Meanwhile, in
positive controls, DNA in the cell lysate was used as a template for PCR to
amplify the Rp sequence (lanes 1 and 6); Rp, an Rp fragment amplified from
pR-Sp1; M, 100 bp ladder.
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also did not result in the synthesis of Rta at a level detectable
by IB (Figure 9A, lane 4 and 5). However, Rta was detected
if the cells were cotransfected with 0.5 mg of pCMV-R and
5 >10 mg of pcDNA-MCAF1 (Figure 9A, lanes 6 and 7).
A similar study was also performed in 293 cells that were
infected with maxi-EBV. Because EBV expresses Rta con-
stitutively in epithelial cells (Figure 9B, lane 2), a low level of
Figure 7. Mapping the interaction domains on MCAF1 and Rta. Plasmid that expresses GFP-MCAF1 and its deletion derivatives (A) was cotransfected with
pCMV-R into 293Tcells.(B) Proteinsin the lysates preparedfrom cells thatexpressGFP (lanes1 and 5), GFP-MCAF-N (lanes 2 and6), GFP-MCAF1-D1 (lanes3
and 7) and GFP-MCAF1-D2 (lanes 4 and 8) were analyzed by IB using anti-GFP antibody (Input) and coimmunoprecipitation (Co-IP) with anti-Rta antibody
and studied by IB with anti-GFP antibody.(C) Plasmids that express Flag-Rta, HA-Rta, GFP-Rtaor Rta deletionmutants were cotransfected with pcDNA-MCAF1
into 293T cells. (D) Cell lysates that contain Flag-Rta (lane 2), Flag-Stu (lane 3), Flag-HincII (lane 4), Flag-HinfI (lane 5), Flag-EcoRII (lane 6), HA-Rta (lane 8),
HA-RN290 (lane 9), GFP-Rta (lane 11) and GFP-R255/290 (lane 12) were immunoprecipitated with anti-MCAF1 antibody and analyzed by IB with anti-Rta
antibody (lanes 1–6), anti-HA antibody(lanes 7–9) and anti-GFPantibody(lanes 10–12).Lanes 1, 7 and 10 were loaded withthe proteinsfrom the cells transfected
with an empty vector.
6534 Nucleic Acids Research, 2005, Vol. 33, No. 20Rta expression was detected in the cells that were transfected
with an empty vector (Figure 9B, lanes 3 and 4). However, the
expression of Rta was markedly higher 1 and 2 days after the
cells had been transfected with 20 mg of pcDNA-MCAF1
5 (Figure 9B, lanes 5 and 6). Meanwhile, the transfection
also led to the expression of another EBV immediate-early
protein, Zta (Figure 9B, lanes 5 and 6). Meanwhile, pcDNA-
MCAF1, pCMV-R and pRRE were also transfected into
293T cells. Transfecting pcDNA-MCAF1 did not increase
10 the capacity of pCMV-R to activate pRRE (data not shown),
suggesting that MCAF1 did not activate the expression of
Rta from the CMV promoter (data not shown). This ﬁnding
shows that the increased Rta expression observed in this
study is caused by the autoregulation of BRLF1 transcription
15 rather than the activation of the CMV promoter by MCAF1.
Activation of an RRE promoter by Rta is independent
of MCAF1 and Sp1
Transfecting pcDNA-MCAF1 had little effect on the activa-
tion of an RRE-reporter plasmid by Rta, so we tested whether
20 the Rta–MCAF1–Sp1 complex could bind to RRE. A DAPA
experiment with a biotin-labeled RRE probe showed that
streptavidin beads could capture Rta (Figure 10A, lane 2).
The beads did not capture Rta when a mutant probe (mRRE),
in which the RRE sequence was mutated, was utilized
Figure 8. Involvement of MCAF1 in Rp autoregulation. Reporter plasmids, pRp (A), pR-Spl (B) and pRRE (C) were cotransfected with pCMV-R and pcDNA-
MCAF1 into P3HR1 cells. (D) Displays the luciferase activity expressed by pRRE and pR-Sp1 after cotransfecting pCMV-R. Luciferase activity was determined
at24haftertransfection.Eachtransfectionexperimentwasperformedatleastthreetimes,andeachsampleintheexperimentswaspreparedinduplicate.Thevalues
obtained from the experiment were analyzed statistically by the least square means method. *, P < 0.05; **, P < 0.01.
Figure 9. ActivationoftheexpressionofEBVimmediate-earlygenesbyMCAF1.(A)P3HR1cells(5 · 10
6)weretreatedwithTPAandsodiumbutyratetoactivate
the expression of Rta (lane 1). Cells untreated with TPA and sodium butyrate were transfected with 20 mg of pcDNA3.1 (lanes 2) and pcDNA-MCAF1 (lanes 3).
Cotransfectionwasalsoperformedbytransfecting0.5mgofpCMV-Rand1–20mgofpcDNA-MCAF1(lanes4–7).Lysateswerepreparedat48haftertransfection.
Immunoblot analysis was performed with anti-Rta and anti-a-tubulin antibodies. (B) 293 cells (5 · 10
6) that were infected by maxi-EBV (lane 2) were transfected
with20mgofpcDNA3.1(lanes3and4)andpcDNA-MCAF1(lanes5and6).Proteinswerepreparedfromthecellsat24h(lanes3and5)and48h(lanes4and6)after
transfection. Lane 1 was loaded with the lysate from 293 cells. Immunoblot analysis was performed using anti-Rta, anti-Zta and anti-a-tubulin antibodies.
Nucleic Acids Research, 2005, Vol. 33, No. 20 6535(Figure 10A, lane 3), indicating that Rta binds to RRE. How-
ever, although Rta binds to MCAF1 (Figure 2), MCAF1 was
not retained by the RRE probe (Figure 10A, lane 2). Addi-
tionally, by testing a panel of mutations in the DNA-binding
5 domain in Rta, we found that the K213 residue in Rta was
critical to its binding to RRE; a lysine to alanine substitution
of this residue (K213A) eliminated the binding capacity of
Rta to RRE (Figure 10A, lane 7). This site was outside the
MCAF1-binding domain, so this mutant protein could be used
10 to establish that activating an Sp1 promoter was independent
of DNA binding. In a transient transfection study, both Rta
and Rta(K213A) activated pR-Sp1 and pSp1-luc in 293T cells
(Figure 10B). However, Rta(K213A) activated an RRE-
reporter plasmid at a level  60% lower than that activated
15 by Rta (Figure 10B). Furthermore, cotransfecting pcDNA-
MCAF1 did not affect the ability of HA, HA-R and
Rta(K213A) to activate the pRRE promoter (Figure 10B).
Activation of Sp1-mediated transcription by Rta
We also tested whether Rta activates cellular promoters that
20 are activated by Sp1, including the promoters of p16, p21
and SNRPN, in an epithelial cell line, 293T. Transfecting
pTA (Figure 11) alone, which contained a luciferase gene
transcribed from a promoter with only a TATA sequence,
expressed a low background value of luciferase activity. How-
25 ever, the activity was activated 6.9-fold by cotransfection
of pCMV-R. In parallel experiments, the p16 promoter was
activated by pCMV-R 14.8-fold; the p21 promoter 8.2-fold
and the SNRPN promoter 11.1-fold (Figure 11).
DISCUSSION
30 Rta is an EBV-encoded transcription factor, which is crucial in
regulating the expression of EBV lytic gene. However, as well
as regulating the EBV genes, Rta binds to Rb to release E2F1
Figure 10. TranscriptionalactivationofRp,anSp1promoterandanRREpromoterbyRta.(A)293TcellsweretransfectedwithpCMV-Randthelysatewasmixed
with biotin-labeled probes, RRE and mRRE. Proteins bound to the probe were captured using streptavidin magnetic beads. Proteins extracted from the beads were
analyzedbyIBwithanti-Rtaandanti-MCAF1antibody.Asimilarstudywasperformedwith293TcellstransfectedwithplasmidsthatexpressedHA-Rta(HA-R)and
Rta(K213A).(B) An emptyvector(HA) andplasmidsthatexpressedHA-Rta (HA-R)and Rta(K213A) (K213A)werecotransfectedwithreporterplasmidspR-Spl,
pSp1-luc,pRREandpGL2-Basic(closedrectangle).Meanwhile,pcDNA-MCAF1wasalsocotransfectedtoexaminewhetherMCAF1influencedthetransactivation
activity of pRRE (open rectangle). The nonspecific activation of the transcription of the luciferase gene in pGL2-Basic by Rta and Rta(K213A) was probably
attributed to a GGGAGG sequence, which resembles an Sp1-binding site, near the cloning site of the plasmid. Luciferase activity was determined at 24 h after
transfection. Each transfection experiment was performed at least three times, and each sample in the experiments was prepared in duplicate.
Figure 11. Activatingthepromotersofp16,p21andSNRPNbyRta.293Tcells
were cotransfected with a reporter plasmid and pCMV-R (closed rectangle)
or an empty vector (open rectangle). The reporter plasmids used herein con-
tained a luciferase gene transcribed from the promoter of p16 (pp16), SNRPN
(pSNRPN)andp21(pp21).PlasmidpTAwasareporterplasmidthatcontained
the TATA sequence of BRLF1. Activation of pTA by Rta was probably attrib-
uted to an Sp1-bindingsequence, GGGAGG, in the multiplecloningsite of the
cloningvector,pGL2-Basic,thatwasusedtoconstructpTA.Luciferaseactivity
was determined at 24 h after transfection. Each transfection experiment was
performedatleastthreetimes,andeachsampleintheexperimentwasprepared
in duplicate.
6536 Nucleic Acids Research, 2005, Vol. 33, No. 20from Rb to affect the cell cycle progression (24). Rta also
modulates the phosphorylation of p38 and c-Jun-N-terminal
kinases, ultimately affecting gene expression (11), indicating
that Rta affects not only the expression of EBV but also the
5 functions of cellular genes. Expression of Rta may be espe-
cially important to epithelial cells since Rta is constitutively
expressed by EBV in these cells (25). Ragoczy et al. (10)
established already that Rta activates the transcription of
BRLF1 through two Sp1 sites in Rp. Sp1 is a crucial tran-
10 scription factor that regulates many cellular genes, including
those involved in housekeeping functions (26), cell differen-
tiation (27), methylation (28) and oncogenesis (29). Hence,
if Rta inﬂuences Sp1-mediated transcription, then the expres-
sion of Rta may profoundly affect the expression of cellular
15 genes. Accordingly, the ultimate goals of this work are to
explore whether and how Rta affects the transcription of
the genes that are activated by Sp1.
A yeast two-hybrid screen was performed and revealed
that an Sp1-binding protein, MCAF1, interacts with Rta.
20 The interaction was then veriﬁed in vitro with bacterially
expressed proteins (Figure 2) and in vivo by immunoprecip-
itation (Figure 3). Additionally, CHIP analysis revealed the
formation of an Sp1–MCAF1–Rta complex on an Sp1 site in
cells (Figure 6). This work also veriﬁes the results of Ragoczy
25 et al. (10), who noted that binding of Rta to Sp1 on an Sp1
probe could not be detected by electrophoretic mobility shift
assay,perhaps because the proteincomplex islarge.The putat-
ive protein–DNA complex might not enter the gel or might
have dissociated during electrophoresis. We therefore used
30 DAPA to search for binding of the protein complex to a
biotin-labeled Sp1 probe (Figure 5). Additionally, a CHIP
assay was performed to verify the binding of these proteins
to the Sp1 site in Rp in vivo. This investigation was originally
conducted in P3HR1 cells following EBV lytic induction. The
35 results indicated that MCAF1, Rta and Sp1 bind to Rp (data
not shown). However, our subsequent investigations showed
that MCAF1 and Rta also form a complex on ZRE
(L.-K. Chang and S.-T. Liu, unpublished data). Only 7 nt
separate the Sp1 site and ZRE in Rp, making it extremely
40 difﬁcult to distinguish the binding of MCAF1 to the Sp1
site or ZRE by CHIP analysis. Therefore, CHIP assay was
conducted by immunoprecipitating the proteins at the Sp1
site in Rp in pR-Sp1 (Figure 4), in which the ZRE was mutated
(Figure 1).
45 We mapped the Rta-binding domain on MCAF1 in the
region between amino acids 650 and 981 (Figure 7B). An
earlier work revealed that the domains in MCAF1 that interact
with Sp1 are located in D1 and D2 (Figure 7A) (14). We
determined that excess Rta does not affect the binding of
50 MCAF1 to Sp1 (Figure 2E), indicating that although the
Sp1- and Rta-binding regions overlap on MCAF1, Rta does
not interfere with the binding of Sp1 to MCAF1. A lysine
to alanine substitution on the K213 residue eliminated the
capacity of Rta to bind to RRE (Figure 10A) and reduced
55 the capacity of Rta to activate an RRE-reporter plasmid
(Figure 10B). The fact that K213 is located outside of the
MCAF1-binding domain and the K213A mutation transactiv-
ates pR-Sp1 and pSp1-luc (Figure 10B) veriﬁes that the trans-
activation of Rp by Rta is independent of RRE binding.
60 Rta contains an RRE-binding domain located between
amino acids 1 and 320 (Figure 7), so the Rta–MCAF1–Sp1
complex might also bind to an RRE. However, our DAPA
study indicates that this is not the case (Figure 10A). Addi-
tionally, transfecting pcDNA-MCAF1 has little effect on the
65 activation of an RRE-reporter plasmid by Rta (Figure 8C),
further indicating that MCAF1 does not participate in that
activation. The lack of activation may be attributed to the
fact that the RRE-binding domain and the MCAF1-binding
domain overlap on Rta (Figure 7); the binding of Rta to RRE
70 may prevent the binding of Rta to MCAF1.
We ﬁnd that Rta activates Rp through Sp1, suggesting that
the expression of Rta may also inﬂuence the transcription of
the cellular genes that are regulated by Sp1. We chose three
important regulating genes, p16, p21 and SNRPN, that contain
75 Sp1 sites to study the capacity of Rta to activate Sp1-mediated
transcription. p16 is a tumor suppressor gene that contains
aberrantly hypermethylated CpG islands in its promoter in
cancer cells (30). p21 is known to regulate cell cycle progres-
sion (31); SNRPN is an imprinted gene, typically unmethy-
80 lated and heavily methylated on the active paternal and
inactive maternal alleles, respectively (32). pCMV-R activates
the promoters of these three cellular genes 10- to 15-fold
in transfection experiments (Figure 11). A reporter plasmid
that contains four of the six Sp1 sites in the p21 promoter,
85 pSp1-luc (Figure 1), is also strongly activated by Rta
(Figure 10B). The BNLF1 promoters contain several Sp1
sites (33,34); the transcription activation of this gene by
Rta probably involves the binding of the Sp1–MCAF1–Rta
complex to these sites. Furthermore, Rta activates the tran-
90 scription of c-myc proto-oncogene (35). The promoter of
this gene lacks an RRE but contains several Sp1 sites near
the TATA sequence (36). These ﬁndings indicate the crucial
role of Rta in regulating Sp1-mediated transcription. More-
over, EBV lytic promoters are typically hypermethylated
95 during viral latency (37,38). Additionally, MCAF1 binds to
MBD1 on CpG sequences to repress gene transcription, so this
laboratory is currently studying how the interaction between
Rta and MCAF1 affects CpG methylation during EBV latent-
lytic switching.
100 One of the important questions addressed herein concerns
the effect of the interactions among Sp1, MCAF1 and Rta on
the activation of the EBV lytic cycle. As is generally known,
BRLF1 is not transcribed during EBV latency in B cells but
is transcribed in epithelial cells (25). Therefore, if MCAF1
105 participates in BRLF1 autoregulation, then transfecting
pcDNA-MCAF1 to epithelial cells that are infected by EBV
may promote expression of Rta from the virus. This, indeed, is
the case; the expression of Rta from maxi-EBV in 293
cells was enhanced after the cells were transfected with
110 pcDNA-MCAF1 (Figure 9B, lanes 5 and 6). Additionally,
the transfection also led to the expression of Zta
(Figure 9A), perhaps through the activation of BZLF1 tran-
scriptionbyRta(11).These observationsindicatethatMCAF1
participates in EBV lytic activation in 293 cells. However,
115 MCAF1 did not activate Rta expression in P3HR1 cells
(Figure 9A). The expression of Rta was only evident when
a little pCMV-R was cotransfected with pcDNA-MCAF1
(Figure 9A, lanes 6 and 7), suggesting that the expression
of Rta is a prerequisite for EBV lytic activation by
120 MCAF1. Moreover, an earlier work demonstrated that
MCAF1 is abundant in the cell, which may explain why trans-
fecting >10 mg of pcDNA-MCAF1 is required to detect the
Nucleic Acids Research, 2005, Vol. 33, No. 20 6537enhancement of the expression of EBV immediate-early
genes (Figure 9).
This work demonstrates that Rta can activate gene trans-
cription by two mechanisms, by which Rta activates not only
5 EBV but also cellular genes, which may ultimately affect cell
cycle progression and oncogenesis. EBV in epithelial cells is
generally known to express Rta constitutively (25). Therefore,
activation of cellular genes and especially an EBV oncogene,
BNLF1, may be crucial to the oncogenesis of the cells. How-
10 ever, Rta expression causes the expression of Zta and activates
the EBV lytic cycle (11). Therefore, the cells die by the lytic
production of EBV virions. Accordingly, the activation of
host genes may only be possible if the lytic productive
cycle is abortive. However, our work seems to indicate that
15 although Rta is constitutively expressed from maxi-EBV in
293 cells, the extent of Rta expression may not sufﬁciently
activate the EBV lytic cycle. Not only was Rta expressed at a
low level, but also the expression of Zta by the cells was
undetected by immunoblot analysis (Figure 9B, lane 2).
20 This low level of Rta expression did not cause the expression
of EA-D (data not shown). Additionally, maxi-EBV in 293
cells released only few virions except when the cells were
treated with TPA and sodium butyrate, or transfected with
a plasmid that expressed Zta (Y.-F. Chiu and S.-T. Liu, unpub-
25 lished data). These results suggest that a low level of Rta
expression in 293 cells may not activate the EBV lytic
cycle. This continuously low level of Rta expression may
inﬂuence the physiology of cells and importantly determine
the pathogenicity of the virus.
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